Shares of Agios Pharmaceuticals (AGIO) rose more than 20% on Monday after management reported that the phase III ENERGIZE-T study, evaluating its sole marketed drug, Pyrukynd (mitapivat) in certain thalassemia patients, achieved its primary and key secondary endpoints. A total of 258 adult participants with transfusion-dependent (TD) alpha- or beta-thalassemia were enrolled in the ENERGIZE-T study. These patients were randomized into two treatment arms — 171 patients who received a 100mg oral dose of Pyruky ...